Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
- PMID: 23559750
- PMCID: PMC3607190
- DOI: 10.6026/97320630009309
Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
Abstract
NS3/4A protease is an important emerging target for the cure of hepatitis C. There are many inhibitors of HCV NS3/4A protease that are passing through the clinical improvement indicating momentous reduction in the viral infection rate of patients. In this study molecular docking via MOE-Dock program was used to evaluate binding interactions of ligands with HCV NS3/4A protease. The docking and experimental results were found in good correlation. The best conformations of ligands were analyzed for binding interactions with the residues of binding cavity of NS3/4A protease. The valuable binding interactions and docking scores were observed for compounds 01, 05, 06, 07, 08 and 09.
Keywords: Binding interactions; HCV NS3/4A protease; Molecular Docking; inhibitors.
Figures




Similar articles
-
Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.Mol Biol Rep. 2014 Jan;41(1):337-45. doi: 10.1007/s11033-013-2867-x. Mol Biol Rep. 2014. PMID: 24234753
-
A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach.Molecules. 2023 Jan 29;28(3):1300. doi: 10.3390/molecules28031300. Molecules. 2023. PMID: 36770965 Free PMC article.
-
Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.J Biomol Struct Dyn. 2018 May;36(7):1713-1727. doi: 10.1080/07391102.2017.1332689. Epub 2017 Jun 7. J Biomol Struct Dyn. 2018. PMID: 28531373
-
Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.Infect Disord Drug Targets. 2006 Mar;6(1):3-16. doi: 10.2174/187152606776056706. Infect Disord Drug Targets. 2006. PMID: 16787300 Review.
-
Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.Curr Med Chem. 2016;23(29):3404-3447. doi: 10.2174/0929867323666160510122525. Curr Med Chem. 2016. PMID: 27160539 Review.
Cited by
-
In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.PLoS One. 2014 Feb 13;9(2):e89109. doi: 10.1371/journal.pone.0089109. eCollection 2014. PLoS One. 2014. PMID: 24551230 Free PMC article.
-
Exploring the antibacterial, antidiabetic, and anticancer potential of Mentha arvensis extract through in-silico and in-vitro analysis.BMC Complement Med Ther. 2023 Jul 26;23(1):267. doi: 10.1186/s12906-023-04072-y. BMC Complement Med Ther. 2023. PMID: 37496047 Free PMC article.
-
Cell Growth Stimulation, Cell Cycle Alternation, and Anti-Apoptosis Effects of Bovine Bone Collagen Hydrolysates Derived Peptides on MC3T3-E1 Cells Ex Vivo.Molecules. 2020 May 14;25(10):2305. doi: 10.3390/molecules25102305. Molecules. 2020. PMID: 32422931 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources